Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 27, 2008 (Fiscal Year 2009)
Business Overview: Haemonetics designs, manufactures, and markets blood management solutions, including devices and disposables for blood donors and patients, as well as software and services for blood and plasma collection centers.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 27, 2008 |
9 Months Ended Dec 27, 2008 |
|---|---|---|
| Net Revenues | $155,447 | $445,482 |
| Gross Profit | $78,296 | $226,022 |
| Gross Margin | 50.4% | 50.7% |
| Operating Income | $24,491 | $67,434 |
| Operating Margin | 15.8% | 15.1% |
| Net Income | $16,216 | $45,365 |
| Diluted EPS | $0.62 | $1.73 |
| Cash & Equivalents | $125,325 | $125,325 |
| Working Capital | $268,358 | $268,358 |
| Net Cash Position | $115,369 | $115,369 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 15.5% for the quarter and 17.9% year-to-date compared to the prior year. Growth was driven by increased disposables sales (particularly Plasma and Surgical/Diagnostic) and equipment sales. Foreign exchange contributed 1.0% to quarterly growth and 3.7% to year-to-date growth.
- Profitability: Operating income rose 25.0% for the quarter and 34.9% year-to-date. Gross margin improved by 90 basis points year-to-date due to manufacturing efficiencies and favorable foreign exchange impacts.
- Acquisitions: Results include the impact of the TEG Thrombelastograph business (acquired Q3 FY2008) and Medicell (acquired Q1 FY2009). TEG contributed $5.3 million in quarterly revenue and $15.0 million year-to-date.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 15.8% quarterly and 18.6% year-to-date, largely due to acquisition-related costs and higher performance-based compensation.
- Cash Flow: Net cash provided by operating activities increased to $72.7 million (9 months) from $45.8 million in the prior year, driven by higher net income and improved collections. Net cash used in investing activities decreased significantly due to lower acquisition spending compared to the prior year.
Guidance, Outlook, and Risks
- Plasma Outlook: Management expects plasma disposable growth rates to moderate to a low double-digit rate over the next 12–24 months as market growth trends down and customer demand normalizes.
- Restructuring: The company is implementing a Technical Operations transformation plan. Once finalized, the company expects to incur exit-related costs in the range of $6 million to $7 million over fiscal year 2009.
- Legal Proceedings: On January 30, 2009 (subsequent to period end), a jury awarded Haemonetics approximately $15.7 million in damages in a patent infringement case against Baxter Healthcare. The verdict is subject to appeal.
- Risks: Key risks include foreign currency exchange rate fluctuations (hedged via forward contracts), reliance on the plasma market, regulatory changes, and the impact of raw material costs (plastics).
- Capital Allocation: The company completed a $60 million share repurchase program during the period, purchasing approximately 1.1 million shares.
Investor Verification Checklist
- Acquisition Integration: Verify the ongoing integration costs and revenue contribution from the TEG and Medicell acquisitions.
- Plasma Market Dynamics: Monitor the moderation of plasma growth rates as indicated by management.
- Restructuring Costs: Track the actual execution and cost of the Technical Operations transformation ($6–7 million range).
- Legal Outcome: Confirm the final status of the $15.7 million patent verdict against Baxter Healthcare, including any appeals.
- Foreign Exchange Exposure: Assess the impact of the strengthening U.S. dollar on future international revenue (53.8% of sales are international).